Abstract 1199P
Background
Homologous recombination repair (HRR) genes play a critical role in tumor DNA damage repair. Loss-of function HRR alternation, including SNV/Indel and homozygous deletion (HD), could predict sensitivity of poly ADP-ribose polymerase (PARP) inhibitor. Therefore, developing a comprehensive and reliable HRR detection approach is necessary.
Methods
In this study, prostate samples (cancer tissue specimens and cell lines) carrying HRR SNV/Indel/HD alterations or wild-type genomes were used to assess the performance of a Next Generation Sequencing (NGS) kit (AmoyDx HRD Complete Panel) for the SNV/Indel/HD detection, which covers 17 HRR genes and 3 tumor-associated genes. The AmoyDx master panel was used as a reference test.
Results
Of the 102 prostate cancer samples (including 19 BRCA1/2 SNV/indel-positive samples and 1 BRCA2 HD-positive sample), positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA) of the two NGS kits for BRCA1/2 detection were all 100%. 8 SNV/Indel-positive samples were constructed into 576 reactions that were validated by gradient dilution and repetition. The limit of detection (LOD) criterion for SNV/Indel were ≥ 5% and the amount of DNA input was 30 ng. Detection sensitivity for HD at the exon level was 100% when tumor purity was greater than 40% and DNA input was 100ng. For gene level HD, tumor purity ≥ 30% was required. 8 SNV/Indel/HD positive or negative (4 SVN/Indel positive, 2 HD positive, 2 SNV/Indel/HD negative) samples were tested repeatedly with different batches of reagents in different time periods. The coefficient of variance (CV) of positive samples was less than 10%, and the negative samples were all negative for repeat testing. In the presence of hemoglobin, triglyceride, and paclitaxel during the extraction process, or ethanol (found in DNA samples), xylene, or proteinase K during the DNA addition, the OPA of testing samples was 100% compared to the reference.
Conclusions
This study demonstrated that Amoydx human homologous recombination repair gene panel exhibited high concordance with AmoyDx master panel and could provide reliable HRR SNV/Indel/HD detection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
X. Lin, Y. Guo, P. Cheng, Z. Huang, C. Zhu: Financial Interests, Institutional, Full or part-time Employment: Amoy Diagnostics Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1482P - Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise?
Presenter: Saurabh Galodha
Session: Poster session 10
1484P - Inflammatory patterns of ascites in patients with solid tumors
Presenter: Julia Berger
Session: Poster session 10
1485P - Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO)
Presenter: Paulo Bergerot
Session: Poster session 10
1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
Presenter: Shani Shilo
Session: Poster session 10
1487P - Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer
Presenter: Shiori Yoshida
Session: Poster session 10
1488P - Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Presenter: Wendy Chan
Session: Poster session 10
1489P - Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Presenter: Sarah Gomes
Session: Poster session 10
1490P - Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study
Presenter: Herald Mapa
Session: Poster session 10
Resources:
Abstract
1491P - Palliative care of E-warm model for driver-gene-negative non-small cell lung cancer patients: A single-center randomized controlled trial
Presenter: Junhui Zhang
Session: Poster session 10
Resources:
Abstract